FHC #140: Diving deep into GLP-1 drug prices and ChatGPT’s newest update

This month’s “Diving Deep” episode, part of the Fixing Healthcare podcast series, takes a close look at two critical topics in the realm of healthcare: OpenAI’s newest update, GPT-4o, and the exorbitant pricing of GLP-1 drugs like Wegovy and Ozempic.

Cohosts Dr. Robert Pearl and Jeremy Corr explore the profound implications that these advancements and challenges hold for the future of medicine.

The episode begins with an in-depth discussion on OpenAI’s GPT-4o update. Dr. Pearl and Corr analyze how this generative AI tool, which now features human-like interactions, can revolutionize healthcare by enhancing diagnostic accuracy, treatment recommendations and patient monitoring.

Next, the conversation shifts to the high costs of GLP-1 drugs such as Wegovy and Ozempic. Dr. Pearl sheds light on why these effective weight-loss medications remain out of reach for many Americans. The discussion includes a critical look at the disparity in global pricing and the urgent need for legislative action to make these life-saving drugs more affordable.

Click play to learn more or check out the various links below for additional information.

HELPFUL LINKS

• OpenAI’s Rule-Shattering GPT-4o Update Will Be Lifesaving, Too (Forbes)
• Wegovy And Ozempic Are Overpriced By 400-500% — Here’s A Quick Solution (Forbes)
• Monthly Musings on American Healthcare (Robert Pearl’s newsletter)

* * *

Dr. Robert Pearl is the author of “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine.” All profits from the book go to Doctors Without Borders.

Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on Twitter and LinkedIn.

The post FHC #140: Diving deep into GLP-1 drug prices and ChatGPT’s newest update appeared first on Fixing Healthcare.